
Recorded Presentation of NCCN Optimizing Patient Outcomes - Precision Immune Targeting: The Rise of Bispecifics in Multiple Myeloma
Target Audience
This program is designed to meet the educational needs of physicians, nurses, nurse practitioners, pharmacists, physician associates and other health care professionals who treat patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Describe the need for newer therapies in the setting of late relapsed/refractory multiple myeloma.
- Discuss pivotal trials surrounding the FDA approval of bispecific antibodies for the treatment of late relapsed/refractory multiple myeloma.
- Identify key patient counseling and monitoring parameters for bispecific antibodies when used for the treatment of late relapsed/refractory multiple myeloma.
Course summary
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 ANCC Pharmacology Contact Hours
- 1.00 Participation

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
![]() | In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. |
Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1.0 pharmacotherapeutic contact hour for nurses.
Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-26-114-H01-P
PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until November 12, 2027. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 ANCC Pharmacology Contact Hours
- 1.00 Participation
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability (speakers or a headset)
- Adobe Reader or other PDF reader software for certificate viewing/printing

Facebook
X
LinkedIn
Forward
